Mary W Redman

10PUBLICATIONS

118CO-AUTHORS

Molecular targetsPredictive and prognostic markersTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|Jun 03, 2026

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

|Jun 04, 2025

Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: A Lung-MAP Study.

Philip C Mack, Mary W Redman, Hanna Tukachinsky

|Apr 10, 2024

A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.

Joel W Neal, Katherine Minichiello, Ryan Brennick

|Jan 26, 2024

Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.

Edwin Roger Parra, Jiexin Zhang, Dzifa Yawa Duose

|Sep 07, 2023

Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP).

Riha Vaidya, Joseph M Unger, Lu Qian

|Jun 09, 2023

Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent Adenomas.

Ming Yu, Kelly T Carter, Kelsey K Baker

Pageof 2

Frequent Collaborators

Roy S Herbst

Karen Kelly

David R Gandara

Karen L Reckamp

Joel W Neal

Philip C Mack

Jhanelle E Gray

David E Kozono

Joseph M Unger

Hossein Borghaei

Frequent Collaborators

Roy S Herbst

Karen Kelly

David R Gandara

Karen L Reckamp